MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008.

Slides:



Advertisements
Similar presentations
THE PHYSICIAN PAYMENTS SUNSHINE ACT
Advertisements

Labeling Prescription Drugs for Physicians and Consumers 48 th Annual Conference Preparing for the Next Century of Food and Drug Regulation Food and Drug.
Adis R&D Insight Sue Shoolbread Editorial Leader 12 June 2006.
Risk Communication Advisory Committee Risk Communication Issues in the Food and Drug Administration Amendments Act of 2007 February 28, 2008.
WHO Good Governance for Medicines programme Technical Briefing Seminar 19 November 2009, Geneva Dr Guitelle Baghdadi-Sabeti Department of Essential Medicines.
1 Physician-Industry Transparency: The U.S. Physician Payment Sunshine Act.
FOCUS ON NLM RESOURCES: CLINICALTRIALS.GOV. WHAT IS A CLINICAL STUDY?  Research study using human subjects.  Volunteers may have a certain disease or.
Registration of Clinical Trials and Resources for Clinical Trial Registration.
Advertising of rx medicinal products to the general public The case MSD Sharpe & Dohme GmbH vs. Merckle GmbH (C-316/09) Judgment of the ECJ of 5 May 2011.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Clinical Trials Registry Susan Koenig, MPP&PA Director, Office of Compliance & Quality University of Missouri-Columbia School of Medicine Compliance &
Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Searching the grey literature : where to look and what to expect Rose Relevo, MLIS, MS Oregon Health & Sciences University Effective Healthcare Program.
Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials.gov Download date: 27 Sept 2010.
A service of the U.S. National Institutes of Health Module 1: Clinical Trials and Requirements for Registration and Results Reporting.
GLOBAL REGULATORY STRATEGY CONSIDERATIONS SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES SEPTEMBER 14-17, 2008 BOSTON, MA.
The Registration of Clinical Trials Deborah A. Zarin, M.D. Director, ClinicalTrials.gov May 2007.
CHOOSING THE APPROPRIATE MEDIUM FOR YOUR PUBLICATION: JOURNAL SELECTION TACTICS SCIENTIFIC LAWRENCE LIBERTI, MS, RPh VP, GENERAL MANAGER JUNE 2008.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
11 February 2008NLM BOR WG on Clinical Trials1 Clinical Trials Registration and Results Reporting: Legislative Requirements Jerry Sheehan Assistant Director.
The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.
*To Err is Human: Building a Safer Health System. National Academy Press, 2001 Why is DynaMed Needed? Between 44,000 and 98,000 American deaths per year.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Copyright © CRF Box, Ltd. All rights reserved. 1 Introduction to Electronic Data Collection Methods; Improving Data Quality and Integrity in Epidemiological.
EVALUATING HEALTH INFORMATION ONLINE Lydia N Collins Consumer Health Coordinator.
New Faculty Orientation August 22, 2012 UAMS Research Support Center Director: Tom Wells (501)
INDs : Does My Study Need One? Edith Paal UAMS Office of Research Compliance August 22, 2003.
Care Planning: Better health begins here... April 2013.
ClinicalTrials.gov Tutorial Chicago Urban Health Outreach Project ClinicalTrials.gov Tutorial Use the buttons below to navigate. Start by clicking the.
A brief overview by Jeremy Quillin.  Criticality- finding the right resource  Knowledge- knowing basic information  Restraint- restraint in legal advice.
The Pharmaceutical Situational Analysis in Mongolia 1 Chimedtseren Munkhdelger 1 Sanjjav Tsetsegmaa 2, 1 Ministry of Health, 2 Pharmacy School, Health.
Key Compliance Risks in Clinical Trials Kathleen Meriwether Principal, ERNST & YOUNG, LLP Fraud Investigation & Dispute Services.
1 Best Practices in Stakeholder Involvement Paul J. Seligman, M.D., M.P.H. Associate Director, Safety Policy & Communication Center for Drug Evaluation.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Presenter name:Noel Juban, M.D, MsC Affiliation: Department of Clinical Epidemiology U.P. College of Medicine November 2011MeTA Process and Lessons from.
Benchmarking Study on the Situation of the United Nations System and Development Institution Websites Results of the World Bank Conference Web for Development:
ClinicalTrials.gov Results Reporting, Unique Evidence, and the Role of Medical Librarians SCR CONNECTions March 19, 2014.
Clinical Writing for Interventional Cardiologists.
NJE rnicHR1 This report is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution.
THE IMPORTANCE OF IPR ACROSS THE LIFECYCLE OF INNOVATION Bob Stembridge Principal Patent Analyst, IP & Science.
Melissa McCarey, MPH Jefferson Clinical Research Institute (JCRI) Clinicaltrials.gov: What is it? What do I need to know?
Trusted evidence. Informed decisions. Better health. Cochrane_QuickRefBooklet.indd 114/8/15 5:41 pm.
Ethical Issues in the Publication of Clinical Trial Information The International Pharmaceutical Compliance Summit on Medical Affairs, Clinical Trials,
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
EBM --- Journal Reading Presenter :蕭皓天 Date : 2005/10/17.
Michael Celestin, MA,CHES,CTTS 3/6/2013 R2R MENTORSHIP EXPERIENCE.
Browse more Reports on Clinical Trials at
Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.
1 AVAREF MEETING – 24 th, September, 2010 Nairobi - Kenya Registry component: Pilot Implementation Experience in Tanzania Fimbo,
Rheumatology Mastery in Ankylosing Spondylitis
ClinicalTrials.gov Requirements
Observational Study Working Group
Background Results Objective Methods Results Conclusions
GCP/QA SIAC Member Meeting 19 January 2007 Pamela Rose, Session Chair
The Information Professional’s Role in Product Safety
Recording and Reporting Clinical Trial Results
Clinical Study Results Publication
Heart Failure Management
HL7 International January Working Group Meeting Health Care Device WG
Heart Failure Management
Can Mobile Technology Improve Outcomes?
Introduction to TransCelerate
Lilly Grant Funding Disclosure May 27, 2008
CLINICAL TRIAL REGISTRIES
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Module 6 Part B: Internet Resources
FDA Sentinel Initiative
Presentation transcript:

MONITORING THE VALUE OF TRIAL REGISTER INFORMATION Thomson Pharmaceutical Services LAWRENCE LIBERTI MS, RPh, RAC JULY 16, 2008

2 SCOPE OF TODAY’S PRESENTATION PRACTICAL ROLE OF REGISTERS FORMATS OF REGISTER PRESENTATION METHODS TO ASSESS ONLINE REGISTER INFORMATION DETERMINING THE VALUE OF REGISTERS TO TARGET USERS CONCLUSIONS

REGISTER vs REGISTRY?

4 WHAT’S IN A NAME? Registry: A repository of ongoing clinical trials – –“Clinical Trial Registry Data Bank” (FDAAA) Register: A repository for the results of clinical trials – –“Results Data Bank” (FDAAA)

THE PRACTICAL ROLE OF REGISTRIES and REGISTERS

6 REGULATORY INITIATIVES State Bills (to amend the PHS Act to expand the clinical trials drug data bank) *******FDAAA September 2008 Title VIII- Clinical Trial Databases********

7 The Maine Precedent Maine law requires manufacturers or labelers of prescription drugs to list information on clinical trials on prescription drugs that have been FDA- approved for marketing and are (or have been) dispensed, administered, delivered or promoted in Maine. Certain registration and results information must be posted on clinical trials conducted or sponsored by the manufacturer on or after October 15, The date by which the information must be posted varies depending on when the trial occurred and when the drug first enters Maine. An Act Regarding Advertising by Drug Manufacturers and Disclosure of Clinical Trials

8

9 THE PRACTICAL ROLE OF REGISTRIES For federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. (Sponsored by US National Institutes of Health)

10 THE PRACTICAL ROLE OF REGISTERS The ClinicalStudyResults.org site is a central, widely accessible, web-based repository for clinical study results in a reader-friendly, standardized format. This database will serve the valuable function of making clinical trial results for many marketed pharmaceuticals more transparent. More importantly, it is designed as a key tool to provide information to practicing physicians and their patients. (Sponsored by PhRMA)

FORMATS OF PRESENTATIONS Study Listings Results Postings

12 STUDY LISTINGS ( ClinicalTrials.gov currently has 58,702 trials with locations in 157 countries

13

14

15 RESULTS POSTINGS Welcome to ClinicalStudyResults.org! The ClinicalStudyResults.org site is a central, widely accessible, web-based repository for clinical study results in a reader-friendly, standardized format. This database will serve the valuable function of making clinical trial results for many marketed pharmaceuticals more transparent. More importantly, it is designed as a key tool to provide information to practicing physicians and their patients.

16 SUMMARY OF THE ROLE OF RESULTS POSTINGS To provide a repository of information To provide a balanced overview of clinical study- derived information To comply with regulatory requirements NOT intended to promote off-label uses NOT intended to provide conclusions

17 WYETH-SPONSORED STUDY

18 GSK APPROACH TO SUMMARY FORMATS

19

20

21 AVANDIA P-1 ONLINE REPORT (GSK)

22 No Conclusions

23 LILLY-SPONSORED STUDY

24

25

26

METHODS TO ASSESS REGISTER INFORMATION

28 METHODS TO ASSESS REGISTER INFORMATION

29 METHODS TO ASSESS REGISTER INFORMATION

30

DETERMINING THE VALUE OF REGISTERS TO TARGET USERS

32 DETERMINING THE VALUE OF REGISTERS TO TARGET USERS RAISES MANY QUESTIONS How will health professionals use register information? –As a primary source of data? –As a back-up to published data How will consumers use the information? What will drive users to registers? What will users remember from registers? Will register data impact knowledge and drug use?

33 UAB STUDY RESULTS Designed to assess how physicians use medical literature to learn about drug therapies CME-accredited program through University of Alabama School of Medicine N = 299 physicians –IM, FP, GP specialties –Urban, suburban, rural practices –1 to > 20 years since medical school Liberti L, Casebeer L, et al: Critical appraisal of medical literature by physicians and its relevance to practice. Presented at the 64th Annual Conference of the American Medical Writers Association, St. Louis, MO, October 2004.

34 THE UAB STUDY RESULTS How much time do you spend reading scientific literature each week? 1-2 hrs30% 3-4 hrs35% 5-6 hrs15% 6-8 hrs10% >8 hrs10% 65% spent up to 4 hrs reading literature

35 CONCLUSIONS Clinicians read in limited time, so information must be positioned: –To a target audience –To have an impact on a thought process –With good information concentrated in specific areas of the article –With clear messages supported by data

36 INFERENCES FOR TRIAL REGISTERS Clinicians have limited time to access and interpret the information Clinicians can distinguish between “solid” and “weak” clinical reports Simplify the data presentation structure, length Provide valid information How can conclusions be drawn without regulatory conflicts? Need to validate new tools to assess the practical value and impact of register information

37 HOW CAN THOMSON REUTERS HELP? –Custom information solutions –Regulatory support –Decision-making support –Database development –Content/editorial support

38 COMPETITORS? TrialTrove ( ADIS Clinical Trials Insight Espicom Pharma & Med Device News FDA News: Drug Pipeline Alert IMS R&D Focus, New Drugs IDIS InPharma NewsRx PHIND PROMT Prous Daily Essentials Scrip Controlledtrials.com The Clinical Trial Registry Platform ( Centerwatch (centerwatch.com) Snow B: Previewing clinical trial results online. November 2005 Liberti L et al: In Search of “Clinical Trial register Version 2.0” in Clinical Trial Registries: A practical Guide for Sponsors and Researchers of Medicinal Products.